[1]Schaefer M, Engelbrecht MA, Gut O, et al.Interferon alpha (IFN alpha) and psychiatric syndromes:a review[J].Prog in Neuro Psychopharmacol Biol Psychiatry, 2002, 26 (4) :731-746.
|
[2]Jessner, Kinaciyan T, Formann E, et a1.Severe skin reac-tions duing therapy for chronic hepatitis C associated with de-layed hypersensitivity to pegylated intefferons[J].Hepatolo-gy, 2002, 36 (4) :361.
|
[3]Primo Vera J.Pegylated interferon-induced diabetes melli tus type1in two patients with chronic hepatitis C[J].Gas troenterol Hepatol, 2004, 27 (2) :69.
|
[4]祝红达, 丁卓玲, 冯丹.α-干扰素在治疗病毒性肝炎时不良反应及分析[J].药物流行病学杂志, 2004, 13 (2) :75-76.
|
[5]宋亚军.长效干扰素治疗慢性乙型肝炎不良反应的观察及护理[J].解放军护理杂志, 2005, 22 (3) :59-60.
|
[6]庄建文.干扰素治疗乙型肝炎患者不良反应分析[J].实用肝脏病杂志, 2006, 9 (6) :356-357.
|
[7]唐翾.干扰素治疗慢性乙型肝炎的不良反应及护理干预[J].现代中西医结合杂志, 2009, 18 (19) :2342-2343.
|
[8]袁炳康.干扰素联合苦参碱治疗慢性乙型肝炎50例[J].临床肝胆病杂志, 2001, 17 (1) :59.
|
[9]王丽萍, 肖海全.α-2a干扰素联合苦参素乙型病毒性肝炎治疗[J].现代中西医结合杂志, 2007, 36 (36) :5455-5456.
|
[10]刘光伟, 王春芳, 叶军, 等.α干扰素联合柴胡颗粒治疗慢性乙肝40例疗效初步观察[J].临床肝胆病杂志, 2008, 24 (1) :45-46.
|
[11]李旭江, 王荣国.α-lb干扰素联合小柴胡汤治疗慢性乙型肝炎[J].临床肝胆病杂志, 2001, 17 (3) :187.
|
[12]郝新洁, 李晓杰, 杜镭.加味当归补血汤预防干扰素副反应的临床观察[J].世界中西医结合杂志, 2010, 5 (2) :154-155.
|
[13]谢立芳, 刘国强.当归拈痛汤加减治疗干扰素流感样不良反应[J].上海中医药杂志, 2005, 39 (9) :95.
|
[14]马国俊, 侯红革, 梁彦玲.强肝解毒汤联合干扰素α-1b治疗慢性乙型肝炎临床研究[J].河南中医学院学报, 2006, 21 (2) :48-49.
|
[15]李长虹, 张海芳, 王吉全, 等.乙肝扶正颗粒联合干扰素治疗慢性乙型肝炎56例临床研究[C]∥.甘肃省中医药学会2008年学术年会论文集[C].甘肃:[出版者不详], 2008.
|
[16]于洪涛, 吴剑华, 康俊杰, 等.康氏系列方联合α-2b干扰素对慢乙肝疗效及副作用的影响[J].湖北中医杂志, 2010, 32 (4) :20-21.
|
[17]王志宏, 岳蓓, 林兰意, 等.针刺联合α-干扰素治疗慢性乙型肝炎临床研究[J].临床肝胆病杂志, 2002, 18 (3) :187-188.
|
[18]张斌, 徐乾, 杜建霞, 等.针刺治疗干扰素骨髓抑制30例临床研究[J].江苏中医药, 2006, 27 (9) :58-59.
|
[1] | Tingting ZHANG, Jue ZHAO, Yan YANG, Yaojie KANG, Xuan WANG. Type 1 diabetes mellitus due to pegylated interferon treatment of chronic hepatitis B: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1905-1906. doi: 10.3969/j.issn.1001-5256.2021.08.031 |
[2] | Gao XiaoHong, Cheng Ni, Cao JiaoJiao. Clinical cure in patients with hepatitis B cirrhosis treated with pegylated interferon α-2b: A case report[J]. Journal of Clinical Hepatology, 2020, 36(6): 1347-1348. doi: 10.3969/j.issn.1001-5256.2020.06.031 |
[3] | Chen Xi, Zhao WenJing, Sun Yan, Yin HaiYan. Value of baseline HBsAg quantification in predicting the clinical effect of pegylated interferon α-2b in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(8): 1723-1726. doi: 10.3969/j.issn.1001-5256.2020.08.009 |
[4] | Ji WeiJia, Yan XueBing. Clinical effect and safety of pegylated interferon-α-2a versus pegylated interferon-α-2b in treatment of chronic hepatitis B [J]. Journal of Clinical Hepatology, 2019, 35(2): 309-314. doi: 10.3969/j.issn.1001-5256.2019.02.013 |
[5] | Li Min, Dan Shan, Wu XiaoNing, Kong YuanYuan, Ou XiaoJuan, You Hong, Jia JiDong. Clinical effect of interferon in treatment of genotype B or C chronic hepatitis B patients: A meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1256-1261. doi: 10.3969/j.issn.1001-5256.2019.06.015 |
[6] | Duan YuanLi, Guan ShiHe, Yang Kai, Chen LiWen, Zhang Hao, Wang Xiu, Pan ZhengLan, Hou ShuWen, Wang ZhaoFei. Serum level of interferon-λ3 in patients with chronic hepatitis B and its clinical significance[J]. Journal of Clinical Hepatology, 2019, 35(2): 315-318. doi: 10.3969/j.issn.1001-5256.2019.02.014 |
[7] | Hepatobiliary Specialized Committee of China Association of Chinese Medicine, Liver Diseases Specialized Committee of China Medical Associa- tion of Minorities. The clinical guidelines of diagnosis and treatment of chronic hepatitis B with traditional Chinese medicine(2018)[J]. Journal of Clinical Hepatology, 2018, 34(12): 2520-2525. doi: 10.3969/j.issn.1001-5256.2018.12.007 |
[8] | Lou Xin, Gao YuFeng, Ye Jun, Wang YinQiu, Guan ZiShu, Zou GuiZhou. Clinical effect of pegylated interferon α-2a in treatment of previously untreated HBeAg-positive chronic hepatitis B patients and related predictive factors[J]. Journal of Clinical Hepatology, 2018, 34(5): 995-1000. doi: 10.3969/j.issn.1001-5256.2018.05.014 |
[9] | Chen Lu, Xie Qing. How to evaluate combination therapy using interferon and nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(11): 2050-2053. doi: 10.3969/j.issn.1001-5256.2016.11.006 |
[10] | Zhang HaiYue, Zhou Pei, Gong ZuoJiong. Predictive value of HBs Ag quantification in pegylated interferon therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(5): 977-980. doi: 10.3969/j.issn.1001-5256.2016.05.041 |
[11] | Wang JingBo, Zhao XiuHong, Cui ShiYu, Li XiaoYing. Interferon-induced adverse reaction of fingernail (toenail) damage: a report of four cases[J]. Journal of Clinical Hepatology, 2015, 31(9): 1485-1487. doi: 10.3969/j.issn.1001-5256.2015.09.030 |
[12] | Shi YiWen, Wang Lin, You Hong. Anti-viral therapy for chronic hepatitis B and cirrhosis: monotherapy or combination?[J]. Journal of Clinical Hepatology, 2015, 31(3): 345-348. doi: 10.3969/j.issn.1001-5256.2015.03.007 |
[13] | Nie HongMing, Chen JianJie, Wang Rong, Shen Hong. Application of interferon-free treatment regimen in treatment of chronic hepatitis C in China[J]. Journal of Clinical Hepatology, 2015, 31(5): 796-799. doi: 10.3969/j.issn.1001-5256.2015.05.041 |
[14] | Yu YiQi, Chen ShaoLong, Zhang WenHong. Research progress in combination therapy with pegylated interferon and nucleos(t)ide analogues in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(9): 1513-1519. doi: 10.3969/j.issn.1001-5256.2015.09.039 |
[15] | Wu HaiQing, Zhao GangDe, Li FengDi, Liu KeHui, Xu YuMin, Lin LanYi, Xie Qing, Wang Hui. Association between IPS- 1 polymorphisms and PEG- IFN treatment response in patients with HBeAg- positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(8): 757-763. doi: 10.3969/j.issn.1001-5256.2014.08.015 |
[16] | He Yan, Tang XiaoPeng, Zheng XuanHe, Yao YunHai, Zhang Quan, Zhang YongHong, Chen Jun. Therapeutic efficacy of combination therapy with interferon and a nucleoside analogue for treating chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2013, 29(2): 114-116+119. |
[17] | Ni Qin, Liu KeZhou. Current issues of antiviral therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2012, 28(3): 172-175. |
[18] | Hepatobiliary Disease Group, Internal Medicine of Traditional Chinese, China Association of Traditional Chinese Medicine, Expert Consensus of Hepatology, World Federation of Chinese Medicine Societies, Hepatology Group, Chinese Association of the Integration of Traditional and Western Medicine. Guidelines for traditional Chinese medical diagnosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2012, 28(3): 164-168. |
[19] | Zhang Tao, Sun KeWei. Experience and progresses of Chinese medicine therapy for hepatitis B-associated liver failure[J]. Journal of Clinical Hepatology, 2012, 28(3): 169-171+182. |
[20] | Zhao Ping, Wang JiangBin, Jiao Jian. Response to PEG-IFN α-2a by chronic hepatitis C patients with autoimmune features[J]. Journal of Clinical Hepatology, 2010, 26(4): 374-376. |